# Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

> **NCT04339777** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 66 (estimated)

## Conditions studied

- Lymphoproliferative Disorders
- Autoimmune Lymphoproliferative
- Immune System Diseases
- Common Variable Immunodeficiency
- Primary T-cell Immunodeficiency Disorders

## Interventions

- **DRUG:** Busulfan test dose
- **DRUG:** Fludarabine
- **DRUG:** Busulfan
- **DRUG:** Alemtuzumab
- **RADIATION:** Total body Irradiation
- **PROCEDURE:** Allogeneic HSCT
- **DRUG:** Tacrolimus (Tacro)
- **DRUG:** Mycophenolate mofetil (MMF)
- **DRUG:** Cyclophosphamide (Cytoxan)

## Key facts

- **NCT ID:** NCT04339777
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-22
- **Primary completion:** 2026-10-01
- **Final completion:** 2027-11-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04339777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04339777, "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04339777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*